Unicycive Therapeutics Inc
UNCY | $1.09 -5.63% -5.96% 890K
|
Professional, Scientific, and T...
(0.0% 1d) (-16.5% 1m) (-31.8% 1y) (0.0% 2d) (3.6% 3d) (-4.9% 7d) (-74.35% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 37,884,515
https://unicycive.com
Sec Filling | Patents | 2021 employees
Unicycive is a biotechnology company developing novel treatment for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury.
treatment kidney
add to watch list Paper trade email alert is off
Press-releases
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
UNCY | $1.09 -5.63% -5.96% 890K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.0%
C: -1.52%
conference therapeutics growth
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
Published: 2024-03-28 (Crawled : 20:00) - globenewswire.com
UNCY | $1.09 -5.63% -5.96% 890K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
business year update financial results
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
UNCY | $1.09 -5.63% -5.96% 890K
|
Professional, Scientific, and T...
|
| O: 1.36%
H: 7.38%
C: 2.01%
congress association renal therapeutics
Unicycive Announces $50 Million Private Placement
Published: 2024-03-14 (Crawled : 11:00) - globenewswire.com
UNCY | $1.09 -5.63% -5.96% 890K
|
Professional, Scientific, and T...
|
| O: 8.63%
H: 14.57%
C: -4.64%
million
Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference
Published: 2024-03-13 (Crawled : 11:00) - globenewswire.com
UNCY | $1.09 -5.63% -5.96% 890K
|
Professional, Scientific, and T...
|
| O: 1.75%
H: 1.03%
C: -4.47%
uni-494 conference presentation therapeutics
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
Published: 2024-03-07 (Crawled : 21:00) - globenewswire.com
UNCY | $1.09 -5.63% -5.96% 890K
|
Professional, Scientific, and T...
|
| O: -6.67%
H: 10.71%
C: 8.57%
trial therapeutics
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients
Published: 2024-03-04 (Crawled : 12:00) - globenewswire.com
UNCY | $1.09 -5.63% -5.96% 890K
|
Professional, Scientific, and T...
|
| O: 1.25%
H: 2.46%
C: -8.02%
uni-494 drug kidney granted food designation therapeutics
Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting
Published: 2024-02-14 (Crawled : 12:00) - globenewswire.com
UNCY | $1.09 -5.63% -5.96% 890K
|
Professional, Scientific, and T...
|
| O: 3.81%
H: 7.34%
C: 6.42%
kidney spring meeting therapeutics
Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference
Published: 2024-01-29 (Crawled : 12:00) - globenewswire.com
UNCY | $1.09 -5.63% -5.96% 890K
|
Professional, Scientific, and T...
|
| O: 5.73%
H: 3.24%
C: 1.61%
uni-494 conference presentation therapeutics
Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones
Published: 2024-01-23 (Crawled : 12:00) - globenewswire.com
UNCY | $1.09 -5.63% -5.96% 890K
|
Professional, Scientific, and T...
|
| O: 4.69%
H: 20.69%
C: 12.99%
key therapeutics
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Last 48 Hours Insiders Buying
SNDA P 3000 | $29.61 3.35% 0.0% 30K
|
n/a
|
22:00
AXR P 2400 | $22.17 2.69% 0.0% 5.5K
|
Finance
|
21:00
FAST P 3350 | $67.5 -1.43% -1.45% 3.6M
|
Distribution Services
|
20:00
QCRH | $55.405 1.33% 1.31% 54K
|
Finance
|
18:01
RVP P 15363 | $1.05 0.96% 0.0% 120K
|
Health Technology
|
18:00
VUZI | $1.26 3.28% 3.17% 1M
|
Electronic Technology
|
18:00
TPL P 3 | $582.4 -0.44% 0.0% 63K
|
Miscellaneous
|
15:00
RELL | $10.15 2.94% 2.86% 94K
|
Electronic Technology
|
13:30
IZEA | $2.65 4.74% 4.53% 31K
|
Technology Services
|
00:00
RKT P 383 | $11.53 1.32% 0.0% 1.6M
|
Finance
|
22:30
CTRN P 18090 | $22.28 -0.4% -0.4% 55K
|
Retail Trade
|
22:00
BRN P 10650 | $2.8 0.36% -0.36% 54K
|
Energy Minerals
|
21:00
NEOG P 10000 | $11.94 -1.65% -1.68% 2.9M
|
Health Technology
|
16:30
RMCF | $3.61 2.27% 2.22% 18K
|
Consumer Non-Durables
|
20:10